Research Funding

DOD CDMRP Opportunities Released

Calls for proposals have been released for the following DoD CDMRP’s:

  • Breast Cancer Research Program:  LOI due June 8
  • Amyotrophic Lateral Sclerosis: LOI due June 9
  • Ovarian Cancer Research Program:  Clinical Development, Investigator-Initiated,and Early Career  LOI due June 21, Pilot Award LOI due June 14
  • Bone Marrow Failure Research Program: LOI due July 13

Full proposals can be found at:  http://cdmrp.army.mil

DoD CDMRP Research Funding for 2017

Department of Defense
United States Army Medical Research Materiel Command
Congressionally Directed Medical Research Programs

CDMRP Research Funding for 2017

The Fiscal Year 2017 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP):

  • Alcohol and Substance Abuse Research Program – $4.0 million
  • Amyotrophic Lateral Sclerosis Research Program – $7.5 million
  • Autism Research Program – $7.5 million
  • Bone Marrow Failure Research Program – $3.0 million
  • Breast Cancer Research Program – $120.0 million
  • Duchenne Muscular Dystrophy Research Program – $3.2 million
  • Epilepsy Research Program – $7.5 million
  • Gulf War Illness Research Program – $20.0 million
  • Hearing Restoration Research Program – $10.0 million
  • Kidney Cancer Research Program – $10.0 million
  • Joint Warfighter Medical Research Program – $50.0 million
  • Lung Cancer Research Program – $12.0 million
  • Lupus Research Program – $5.0 million
  • Military Burn Research Program – $8.0 million
  • Multiple Sclerosis Research Program – $6.0 million
  • Neurofibromatosis Research Program – $15.0 million
  • Orthotics and Prosthetics Outcomes Research Program- $10.0 million
  • Ovarian Cancer Research Program – $20.0 million
  • Parkinson’s Research Program – $16.0 million
  • Peer Reviewed Alzheimer’s Research Program – $15.0 million
  • Peer Reviewed Cancer Research Program (14 Topics) – $60.0 million
  • Peer Reviewed Medical Research Program (48 Topics) – $300.0 million
  • Peer Reviewed Orthopaedic Research Program – $30.0 million
  • Prostate Cancer Research Program – $90.0 million
  • Reconstructive Transplant Research Program – $12.0 million
  • Spinal Cord Injury Research Program – $30.0 million
  • Tick-Borne Disease Research Program – $5.0 million
  • Trauma Clinical Research Program – $10 million
  • Tuberous Sclerosis Complex Research Program – $6.0 million
  • Vision Research Program – $15.0 million

Comprehensive Program Announcements will be released during 2017. The Program Announcements will include detailed descriptions of funding mechanisms, evaluation criteria, submission requirements, and deadlines. Each Program Announcement may be downloaded from the Grants.gov website https://www.grants.gov, or the CDMRP website http://cdmrp.army.mil upon its release.

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org.

For more information about the CDMRP, our research programs, previous awardees, as well as research highlights and videos, please visit the website at http://cdmrp.army.mil.

Point of Contact:

CDMRP Public Affairs
301-619-7783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

 

DoD Preannouncement for Peer Reviewed Medical Research

The Defense Health Program Department of Defense Peer Reviewed Medical Research Program

Funding Opportunities for Fiscal Year 2016

The Fiscal Year 2016 (FY16) Defense Appropriations Act provides $278.7 million to the Department of Defense Peer Reviewed Medical Research Program (PRMRP). The vision of the PRMRP is to improve the health and well-being of all military Service members, Veterans, and beneficiaries. The PRMRP challenges the scientific and clinical communities to address one of the FY16 congressionally directed topic areas with original ideas that foster new directions in basic science and translational research; novel product development leading to improved therapeutic or diagnostic tools; synergistic, multidisciplinary research programs; or clinical trials that address an immediate clinical need.

The PRMRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY16 PRMRP Program Announcements and General Application Instructions are anticipated to be posted on Grants.gov by late March 2016. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

Congressionally Directed Topic Areas. The FY16 PRMRP will solicit research applications for the following 39 topics areas:

  • Acute Lung Injury
  • Antimicrobial Resistance
  • Chronic Migraine and Post-Traumatic Headache
  • Congenital Heart Disease
  • Constrictive Bronchiolitis
  • Diabetes
  • Dystonia
  • Emerging Infectious Diseases
  • Focal Segmental Glomerulosclerosis
  • Fragile X Syndrome
  • Hepatitis B
  • Hereditary Angioedema
  • Hydrocephalus
  • Inflammatory Bowel Disease
  • Influenza
  • Integrative Medicine
  • Interstitial Cystitis
  • Lupus
  • Malaria
  • Metals Toxicology
  • Mitochondrial Disease
  • Nanomaterials for Bone Regeneration
  • Nonopioid Pain Management
  • Pancreatitis
  • Pathogen-Inactivated Dried Plasma
  • Polycystic Kidney Disease
  • Post-Traumatic Osteoarthritis
  • Psychotropic Medications
  • Pulmonary Fibrosis
  • Respiratory Health
  • Rett Syndrome
  • Rheumatoid Arthritis
  • Scleroderma
  • Sleep Disorders
  • Tinnitus
  • Tuberculosis
  • Vaccine Development for Infectious Disease
  • Vascular Malformations
  • Women’s Heart Disease

Military Relevance:Relevance to the healthcare needs of the military Service members, Veterans, and beneficiaries is a key feature of each FY16 PRMRP award mechanism.

Clinical Trial Award

Assistant Professor level or above (or equivalent)

Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.

Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.

Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration before the PRMRP Grants.gov application submission deadline.

Preproposal submission is required; application submission is by invitation only

Funding limit not defined; requested funding must be appropriate for the scope of work proposed

Maximum period of performance is 5 years

Discovery Award

All Investigators

Supports the exploration of a highly innovative new concept or untested theory.

Not intended to support the logical progression of an already established line of questioning.

Clinical trials will not be funded.

Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s)

Maximum of $200,000 for direct costs (plus indirect costs)

Maximum period of performance is 18 months

Focused Program Award

Full Professor level or above (or equivalent)

Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal in one of the topic areas listed directly above. Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications. Projects may range from exploratory/ hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question. Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.

Preproposal submission is required; application submission is by invitation only.

Maximum of $10 million for total costs (includes direct and indirect costs)

Maximum period of performance is 5 years

Investigator-Initiated Research Award

Assistant Professor level or above (or equivalent)

Supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.

Partnering PI Option available.

Clinical trials will not be funded.

Preproposal submission is required; application submission is by invitation only.

Maximum of $1.2 million for direct costs (plus indirect costs)

Maximum of $1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option

Maximum period of performance is 3 years

Technology/ Therapeutic Development Award

Assistant Professor level or above (or equivalent)

Supports the development of diagnostics or therapies that have the potential to make a strong impact on patient care in the topic area(s) of interest.

Product-oriented (e.g., device, drug, clinical guidelines).

Clinical trials will not be funded.

Preproposal submission is required; application submission is by invitation only

Maximum of $3.0 million for direct costs (plus indirect costs)

Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. Requests for email notification of the Program Announcements’ release may be sent to help@ebrap.org. For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs

301-619-9783

mailto:usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

Classification: UNCLASSIFIED Caveats: NONE